Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Giant Cell Tumor

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Giant Cell Tumor

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 1 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00680992 · Source cited / selected · Scope: narrower

      Study of Denosumab in Subjects With Giant Cell Tumor of Bone

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      Indication-specific source history

      Dated source events, not confirmation of current approval for every use of a drug.

      2025-02-14 · vimseltinib · approval notification
      release id
      clinical-indications-draft-1
      disease state id
      ds-giant-cell-tumor
      event id
      notice-653a96891212a1e1
      event date
      2025-02-14
      event kind
      approval-notification
      drug or regimen
      vimseltinib
      source indication text
      FDA approved vimseltinib, a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
      match phrase
      giant cell tumor
      match status
      candidate
      status category
      Source null
      has date discrepancy
      0
      source collection
      fda-approval-notice
      source key
      fda-969b151e3e3b8fb3
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-giant-cell-tumor
        binding id
        ncit-C3055
        source collection
        ncit-concept
        source key
        C3055
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice